Biotechnology

Viracta Therapeutics

Viracta Therapeutics Announces Layoffs and Cessation of Operations

Viracta Therapeutics Evaluates Strategic Options to Address Virus-Related Cancers

Viracta Therapeutics Announces Exploration of Strategic Options

Rodman & Renshaw Downgrades Viracta Therapeutics (VIRX.US) Rating to Neutral, Target Price Reduced to $0.25

Viracta Therapeutics released FY2024 Q3 earnings on November 13 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.2666 USD (forecast -0.245 USD)

Viracta Therapeutics released FY2024 Cumulative Q3 Earnings on November 13, 2024 (EST), with Revenue at 0 and EPS at -0.7485

Viracta Therapeutics: Layoffs of approximately 23%

Viracta Therapeutics Announces Positive Results from NAVAL-1 Trial Phase 1

Viracta Therapeutics released FY2023 Cumulative 3Q Earnings on November 9, 2023 (EST), with Revenue at 0 and EPS at -0.9694

Mega Fortune

Processa Pharmaceuticals

cbdMD

Agape ATP

VYNE Therapeutics

Andersen

Inspirato

Medline

Creative Global Tech

GCI LIBERTY INC COM USD0.01 SER C SUBS RTS 17/12/2025

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap